Novavax may take nano-RSV vaccine forward without pharma
This article was originally published in Scrip
Executive Summary
Novavax is hoping to conduct later-stage clinical trials after reporting positive top-line Phase II data for its respiratory syncytial virus (RSV) F protein nanoparticle vaccine candidate in women of child-bearing age demonstrating both safety and immunogenicity of the vaccine for use in a maternal immunisation strategy.